Opendata, web and dolomites

SIRENE

Silencing miR-199b to attenuate the progression of heart failure.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SIRENE project word cloud

Explore the words cloud of the SIRENE project. It provides you a very rough idea of what is the project "SIRENE" about.

mirnas    species    profound    endogenous    strategic    hypertrophic    commercial    molecules    therapeutics    simultaneously    interconnected    rats    adult    found    pressure    mirna    venture    principal    symptoms    web    micrornas    models    coding    strength    strategy    signalling    class    calmirs    proposition    morphological    feasibility    pathological    arrhythmias    powerful    dose    longer    protective    clinically    risk    rescue    sustained    animal    affinity    market    knockdown    shown    presenting    stage    abnormalities    preclinical    199b    consolidate    larger    silencing    clinical    antagonists    rna    hypertrophy    heart    recognition    mice    overload    histological    demonstrates    specificity    therapeutic    vivo    regulate    holds    ip    model    business    efficacy    functional    cardiac    generation    molecular    marks    counteracting    newly    mir    capitalists    lethal    erc    sirene    leads    mouse    commercialisation    promise    implicated    valuable    data   

Project "SIRENE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2017-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 150˙000.00

Map

 Project objective

Cardiac hypertrophy is the principal risk factor for the development of heart failure and lethal arrhythmias. A complex web of interconnected signalling pathways has been implicated in hypertrophy and species of non-coding RNA molecules, microRNAs, have been shown to regulate these pathways. The recognition of microRNAs as potential therapeutic targets marks the principal step towards new therapeutic concepts. The SIRENE project represents the advancement of the therapeutic strength of miRNA silencing in clinically relevant heart failure models towards a valuable proposition for counteracting pathological hypertrophic signalling and heart failure development. In specific, during the related ERC CALMIRS project, it was found that sustained knockdown of endogenous miR-199b in the adult mouse heart in vivo leads to profound protective effects against symptoms of heart failure. Therefore, a new class of RNA antagonists, targeting miRNAs is powerful and holds great promise to become the next generation therapeutics. At this stage the newly developed antagonists are unique in their affinity and specificity for miR-199b and current data demonstrates a profound rescue by miR-199b antagonists on heart failure symptoms such as pressure overload induced cardiac morphological, histological, functional and molecular abnormalities in mice. The challenge of the SIRENE project is to identify immediate and longer term opportunities for commercialisation with high clinical and commercial feasibility. Therefore different business models will be studied in terms of market research, IP strategy and business development to eventually consolidate a commercial strategy and business case for presenting our business proposition to strategic partners or venture capitalists. Simultaneously, dose-range finding and efficacy studies will be conducted in rats, a clinically relevant and larger animal model of heart failure, for further preclinical development.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIRENE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIRENE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More  

TRUST (2018)

Truth and Semantics

Read More  

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More